# India Liquid Biopsy Market

> India Liquid Biopsy Market Research Report By Types (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, Others), By Application (Cancer Therapeutic Application, Reproductive Health, Others) and By Sample (Blood Sample, Urine Sample, Other) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 10.52%
- **2024:** $ 363.96 Million
- **2025:** $ 402.25 Million
- **2035:** $ 1,093.72 Million
- **Key Players:** Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Qiagen (DE)

**Report ID:** MRFR/HC/42983-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-liquid-biopsy-market-44663

---

## Market Summary

## **India Liquid Biopsy Market Overview**

As per MRFR analysis, the India Liquid Biopsy Market Size was estimated at 411.69 (USD Million) in 2023.The India Liquid Biopsy Market Industry is expected to grow from 580.0(USD Million) in 2024 to 1,230.0 (USD Million) by 2035. The India Liquid Biopsy Market CAGR (growth rate) is expected to be around 7.073% during the forecast period (2025 - 2035)

### **Key India Liquid Biopsy Market Trends Highlighted**

The India Liquid Biopsy Market is seeing significant growth driven by an increasing prevalence of cancer and a rising demand for non-invasive diagnostic methods. The government of India has been focusing on improving cancer care through various initiatives, such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS), aimed at enhancing early detection and treatment. This creates a favorable environment for liquid biopsy technologies, as they offer earlier diagnosis with less patient discomfort compared to traditional tissue biopsies.

Opportunities are emerging in India as healthcare facilities begin adopting these advanced diagnostic solutions.There is an increasing collaboration between public health institutions and private companies, which is fostering innovation in liquid biopsy tests, particularly in personalized medicine tailored to the genetic profile of patients. The rise of start-ups and research institutions working on liquid biopsy technologies is another opportunity, as they are often more agile in developing and commercializing new diagnostics tailored to the Indian patient population.

Trends in recent times include a heightened awareness among healthcare professionals and patients about the potential benefits of liquid biopsies, such as better monitoring of tumor response to therapy and lower risk of complications.Additionally, advancements in molecular biology and technology are creating more efficient and reliable tests. The adoption of technology in diagnostics, enhanced data analysis capabilities, and the use of artificial intelligence to interpret biopsy results are transforming the landscape of oncology in India. As healthcare infrastructure continues to expand, the liquid biopsy market is likely to become an integral part of cancer care in the country.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **India Liquid Biopsy Market Drivers**

### **Increasing Prevalence of Cancer in India**

The rising number of cancer cases in India is a significant driver for the India Liquid Biopsy Market industry. According to reports from the Indian Council of Medical Research (ICMR), cancer incidence is projected to increase to over 1.5 million cases by 2025, reflecting a surge of approximately 27% from previous years.

The growing burden of various types of cancers, including breast, lung, and colorectal cancers, creates an urgent demand for advancements in diagnostics such as liquid biopsies.Organizations such as Tata Memorial Centre and All India Institute of Medical Sciences (AIIMS) are leading efforts to enhance cancer detection and treatment protocols, thereby supporting market growth. The rise in cancer patients indicates an expanding requirement for non-invasive diagnostic tools like liquid biopsies, positioning the industry favorably for future growth.

### **Technological Advancements in Liquid Biopsy Techniques**

Advancements in the technology and methodologies used in liquid biopsy are significantly propelling the India Liquid Biopsy Market industry. Recent developments have led to higher sensitivity and specificity in detecting circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). For example, initiatives by the Indian government to foster biotechnology innovations can be seen in policies that promote research and development in genetic testing technologies.As more diagnostic companies, such as Biocon and Dr. Reddy's Laboratories, invest in technological enhancements, it is expected that these innovations will lead to the adoption of liquid biopsies in standard cancer care, further driving market expansion.

### **Growing Awareness and Acceptance of Non-invasive Procedures**

There is an increasing awareness among patients and healthcare professionals regarding the advantages of non-invasive diagnostic techniques, which is driving the India Liquid Biopsy Market. Educational campaigns by organizations, including the Indian Cancer Society, have helped awareness about the benefits of liquid biopsies for monitoring cancer treatment and detecting recurrences. Gallup polls indicate that nearly 70% of patients prefer non-invasive options over traditional invasive biopsies when available.This rising patient demand for safer diagnostic alternatives encourages healthcare providers to incorporate liquid biopsy technologies into clinical practices, thereby expanding the market's potential.

## **India Liquid Biopsy Market Segment Insights**

### **Liquid Biopsy Market Types Insights**

The India Liquid Biopsy Market is evolving rapidly, driven by the increasing demand for non-invasive cancer diagnostics and monitoring. Within the Types segment, various categories such as Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Extracellular Vesicles (EVs), and Others contribute to the diverse landscape of liquid biopsy solutions. CTCs, which are vital for understanding tumor metastasis and disease progression, play a significant role in personalizing treatment plans and monitoring therapeutic efficacy. ctDNA analysis provides insights into tumor genomics, enabling early cancer detection and the identification of mutations that guide targeted therapies, making it a valuable tool for oncologists.

EVs, on the other hand, facilitate intercellular communication and carry biomolecules that can serve as potential biomarkers for various malignant conditions, reinforcing their importance in the liquid biopsy realm. The segment termed 'Others' encompasses additional innovative technologies and methodologies that continue to emerge, expanding the diagnostic capabilities within the liquid biopsy framework.

Overall, the segmentation of the India Liquid Biopsy Market highlights a comprehensive approach toward cancer management, driven by advancements in molecular biology and genomic technologies, all while emphasizing the need for improved patient outcomes and precision medicine strategies in the Indian healthcare landscape.As the market develops, ongoing research and advancements in these types underline the potential for substantial impacts on cancer diagnostics and treatment paradigms in India.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Liquid Biopsy Market Application Insights**

The Application segment of the India Liquid Biopsy Market encompasses a diverse range of areas, significantly impacting the diagnostic landscape in the country. [Pet Cancer Therapeutic](../../../reports/pet-cancer-therapeutic-market-37119) Applications have emerged as a primary focus, addressing the challenges of early detection and personalized treatment for various cancers prevalent in India, helping to enhance patient outcomes and optimize therapeutic strategies. Reproductive Health is another crucial area, increasing in relevance as non-invasive methods for monitoring genetic conditions and overall reproductive health gain traction.

Moreover, other applications contribute to a well-rounded approach, catering to various diagnostic needs beyond cancer and reproductive health, tapping into significant demand across the healthcare system. The growth in this segment is driven by rising awareness of liquid biopsy's benefits, advancements in technology, and a push for precision medicine. As the healthcare infrastructure in India continues to evolve, the importance of these applications is likely to increase, aligning with trends towards personalized and preventive healthcare. The India Liquid Biopsy Market revenue is poised for significant growth, reflecting the escalating demand for reliable and less invasive diagnostic solutions.

### **Liquid Biopsy Market Sample Insights**

The India Liquid Biopsy Market reflects a growing interest in non-invasive diagnostic tools, with the Sample segment, specifically, playing a pivotal role. Blood samples are increasingly favored due to their ability to provide real-time insights into cancer dynamics, paving the way for timely interventions. Urine samples also present a promising avenue, offering a less invasive option that is easy to collect and has emerging potential for specific cancers. The Other category encompasses a range of bodily fluids that can yield valuable biomarkers, thus enhancing the diagnostic landscape.

Overall, advancements in technology and growing preferences for minimally invasive testing are driving the significance of these sample types within the India Liquid Biopsy Market. As healthcare evolves, the demand for efficient and patient-friendly diagnostic methods is expected to support growth across these various samples, making them integral to the market's progression. Furthermore, the increasing prevalence of cancer in India emphasizes the necessity for effective and accessible liquid biopsy methods, reinforcing their importance in both clinical and research settings.The combination of these factors solidifies the collective impact of the .

## **India Liquid Biopsy Market Key Players and Competitive Insights******

The India Liquid Biopsy Market is experiencing a transformative phase as advancements in technology pave the way for innovative diagnostic techniques. Liquid biopsy, an emerging field that allows for non-invasive cancer screening and monitoring, has gained significant traction in India due to the rising prevalence of cancer and the need for early diagnosis. This market is characterized by a growing number of players focusing on the development of advanced methodologies and products that enhance precision and turnaround time in diagnostics. The increasing collaboration between research institutions and biotechnology firms is also contributing to the evolution of this market.

Competitive insights reveal a landscape where companies are leveraging their expertise in genomics and molecular biology to establish a solid market presence and introduce novel solutions tailored to the specific challenges faced in India.Natera is establishing a notable footprint in the India Liquid Biopsy Market by leveraging its advanced technologies in genetic testing and personalized medicine. The company specializes in non-invasive prenatal testing, but its core competency extends to oncology, where it offers innovative liquid biopsy solutions that allow for real-time monitoring of cancer progression.

With a strong focus on precision medicine, Natera's strengths lie in its strong research capabilities and its commitment to providing actionable insights through its advanced testing methodologies. The ability to deliver tailored treatment options and minimize trial delays is becoming increasingly important in the Indian context, positioning Natera favorably among healthcare providers and patients seeking next-generation cancer diagnostic tools.MyoKardia is another significant player impacting the India Liquid Biopsy Market, particularly through its focus on innovative therapeutic solutions for cardiovascular diseases, which aligns with the broader healthcare challenges faced in India.

Although primarily recognized for its work in drug development, MyoKardia is expanding its horizons into the realm of diagnostics, fostering growth potential within the liquid biopsy sector. The company’s strategic approach includes the development of assays that cater to the unique genetic profiles of patients, enhancing the precision of diagnoses and treatments. MyoKardia aims to strengthen its market presence through collaborations with local healthcare systems and research institutes. Its commitment to innovation, alongside a pipeline of promising products, contributes to its overall strength in the market.

By continually exploring mergers and acquisitions that bolster its expertise in genetics and diagnostics, MyoKardia is well-positioned to play a critical role in advancing liquid biopsy applications across India’s healthcare landscape.

**Key Companies in the India Liquid Biopsy Market Include**

## **India Liquid Biopsy Market Industry Developments**

The India Liquid Biopsy Market has seen significant developments recently, with several companies actively trying to enhance their positions. In September 2023, Natera announced the expanding availability of its tests within the Indian healthcare system, aiming to improve the early detection of cancers. Concurrently, Roche Diagnostics is advancing its liquid biopsy technology for oncology applications, emphasizing the importance of non-invasive diagnostics. Illumina has also been focusing on partnerships with local laboratories to enhance genomic profiling capabilities.In terms of mergers and acquisitions, Cancer Genetics acquired Cernostics in August 2023, enabling a broader portfolio of liquid biopsy services in India.

This strategic acquisition is expected to strengthen Cancer Genetics' market presence in the rapidly growing oncology diagnostics sector. The market valuation for liquid biopsy companies in India is increasing significantly, driven by rising awareness, technological advancements, and a growing demand for early cancer detection methodologies. Additionally, in 2022, OncoStem Diagnostics received regulatory approval for its liquid biopsy test, providing another boost to its market position. Overall, the liquid biopsy market in India is poised for robust growth and is influenced by innovative technologies and strategic partnerships among key players.

## **India Liquid Biopsy Market Segmentation Insights**

### **Liquid Biopsy Market****Types****Outlook**

- 

### **Liquid Biopsy Market****Application****Outlook**

- 

### **Liquid Biopsy Market****Sample****Outlook**

-

## Market Drivers

### Advancements in Biomarker Discovery

Recent advancements in biomarker discovery are significantly influencing the liquid biopsy market in India. The identification of novel biomarkers has enhanced the ability to detect various cancers at earlier stages, which is crucial for effective treatment. This progress is likely to lead to an increase in the adoption of liquid biopsies, as they can provide real-time insights into tumor dynamics. The liquid biopsy market is expected to see a substantial increase in revenue, with estimates suggesting a rise to $500 million by 2027. This growth is indicative of the potential for liquid biopsies to revolutionize cancer diagnostics and patient management.

### Growing Demand for Non-Invasive Diagnostics

The liquid biopsy market in India is experiencing a surge in demand for non-invasive diagnostic methods. Patients and healthcare providers are increasingly favoring liquid biopsies due to their ability to provide critical information with minimal discomfort. This shift is particularly evident in oncology, where traditional tissue biopsies can be invasive and painful. The liquid biopsy market is projected to grow at a CAGR of approximately 20% over the next five years, driven by the need for early cancer detection and monitoring. As awareness of these benefits spreads, more healthcare facilities are adopting liquid biopsy technologies, thereby expanding the market's reach and accessibility.

### Supportive Government Policies and Initiatives

Supportive government policies and initiatives are playing a crucial role in the growth of the liquid biopsy market in India. The government is actively promoting the adoption of advanced diagnostic technologies through funding and regulatory support. Initiatives aimed at enhancing healthcare infrastructure and accessibility are likely to facilitate the integration of liquid biopsy technologies into routine clinical practice. The liquid biopsy market stands to benefit from these favorable conditions, as increased government backing can lead to accelerated market growth. With ongoing support, the market may experience a robust expansion, potentially doubling in size within the next decade.

### Rising Awareness Among Healthcare Professionals

There is a growing awareness among healthcare professionals regarding the benefits of liquid biopsies in cancer diagnostics. Educational initiatives and training programs are being implemented to inform clinicians about the advantages of using liquid biopsies over traditional methods. This increased knowledge is likely to drive the adoption of liquid biopsy technologies in clinical practice. The liquid biopsy market is poised for growth as more healthcare providers recognize the potential for improved patient outcomes. As awareness continues to rise, the market could see a significant uptick in usage, contributing to an overall increase in diagnostic efficiency.

### Increased Investment in Research and Development

Investment in research and development (R&D) is a key driver for the liquid biopsy market in India. Both public and private sectors are channeling funds into innovative technologies that enhance the accuracy and reliability of liquid biopsies. This influx of capital is fostering collaborations between academic institutions and biotech companies, leading to the development of cutting-edge solutions. The liquid biopsy market is likely to benefit from these advancements, as improved technologies can lead to higher adoption rates among healthcare providers. As R&D continues to flourish, the market is expected to expand, potentially reaching a valuation of $1 billion by 2030.

## Future Outlook

The [Liquid Biopsy Market](https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710) in India is projected to grow at a 10.52% CAGR from 2025 to 2035, driven by technological advancements and increasing cancer prevalence.

**New opportunities:**

- Development of portable liquid biopsy devices for remote diagnostics. Partnerships with healthcare providers for integrated testing solutions. Expansion into personalized medicine through targeted biomarker identification.

By 2035, the liquid biopsy market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Cancer Diagnosis (Largest) vs. Treatment Monitoring (Fastest-Growing)

In the India liquid biopsy market, the application segments exhibit diverse dynamics. Cancer Diagnosis remains the dominant segment due to its critical role in the early detection and management of cancer, commanding a significant market share. Treatment Monitoring, while currently smaller in scale, has been gaining traction as healthcare providers increasingly prioritize personalized treatment approaches and the need for continuous assessment of therapy efficacy.

The growth trends reveal an emerging focus on Treatment Monitoring as healthcare systems are evolving to adopt more precise and less invasive methods to track patient responses to therapies. Factors such as technological advancements in liquid biopsy and rising cancer incidences are driving these changes. Clinical Trials and Research Applications are also positioned for growth, fueled by increasing investments in oncology research.

Cancer Diagnosis: Dominant vs. Treatment Monitoring: Emerging

The Cancer Diagnosis segment holds a commanding position in the India liquid biopsy market, characterized by its established applications in detecting various cancers at early stages, which enhances treatment success rates. It leverages advanced technologies to analyze biological samples, ensuring high accuracy and reliability. On the other hand, Treatment Monitoring is emerging as a vital segment, reflecting the need for ongoing patient management. It focuses on evaluating treatment responses in real time, which is crucial for adapting therapy plans. This segment benefits from patient-centric healthcare trends, as clinicians seek to provide tailored treatments based on individual responses. Both segments are crucial, yet they serve distinct roles in improving cancer care outcomes.

### By Sample Type: Blood (Largest) vs. Urine (Fastest-Growing)

The India liquid biopsy market showcases a diverse sample type landscape, with blood samples holding the largest market share due to their widespread acceptance and relative ease of collection. Blood tests are often the preferred choice for oncologists and healthcare professionals, leading to increased adoption across various diagnostic applications. In contrast, urine samples are rapidly gaining traction, driven by advancements in technology and a growing preference for non-invasive testing methods.

The growth trends in the sample type segment are characterized by an increase in the adoption of liquid biopsy tests across healthcare settings. The rise of personalized medicine, combined with an emphasis on early detection of diseases, is propelling the demand for urine samples, which offer a comfortable alternative for patients. Technological advancements further enhance the accuracy and reliability of these non-invasive tests, fostering a favorable environment for their expansion in the India liquid biopsy market.

Blood (Dominant) vs. Urine (Emerging)

Blood sample tests in the India liquid biopsy market remain the dominant choice due to their established reliability and accuracy in detecting biomarkers associated with various cancers. Conversely, urine samples are emerging as a viable alternative, particularly in scenarios where non-invasive methods are preferred. While blood testing has a stronghold driven by existing practices and physician recommendations, urine-based tests are witnessing significant growth owing to their ease of collection and ability to provide valuable diagnostic information without invasive procedures. This shift is attributed to an increasing awareness of the importance of early diagnosis and patient comfort, which positions urine samples as an attractive emerging option in the evolving landscape of the India liquid biopsy market.

### By Technology: Next Generation Sequencing (Largest) vs. Digital PCR (Fastest-Growing)

In the India liquid biopsy market, Next Generation Sequencing (NGS) holds the largest market share, being favored for its high-throughput capabilities and comprehensive genomic insights. Digital PCR, while currently smaller in market share, is gaining traction quickly due to its precision and ability to detect low-abundance variants, making it an attractive option for early cancer detection and monitoring.

The growth trends in this segment are being driven by technological advancements and an increasing focus on personalized medicine. NGS is buoyed by its extensive applications across oncology, while Digital PCR's rapid growth is propelled by its application in clinical diagnostics and research settings. The emergence of microfluidics, exosome isolation, and circulating tumor cells as reliable methods is expected to complement these leading technologies in the forecast period.

Technology: Next Generation Sequencing (Dominant) vs. Digital PCR (Emerging)

Next Generation Sequencing (NGS) stands out as the dominant technology within the India liquid biopsy market, offering unmatched data richness and analysis capabilities for oncological applications. Its ability to sequence millions of fragments simultaneously facilitates comprehensive mutation detection, crucial for personalized treatment strategies. In contrast, Digital PCR is emerging as a competitive technology, known for its sensitivity and accuracy in quantifying nucleic acids. It is particularly beneficial in the detection of minimal residual disease, making it vital in cancer monitoring. Both technologies complement each other, with NGS's broad applicability and Digital PCR's precision positioning them as essential tools in the future of liquid biopsy diagnostics.

### By End Use: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the India liquid biopsy market, hospitals constitute a significant share, primarily driven by their comprehensive healthcare services and advanced diagnostic capabilities. They play a pivotal role in managing a wide variety of conditions, thereby facilitating early cancer detection and treatment with liquid biopsy techniques. Conversely, diagnostic laboratories are experiencing rapid growth as they become central to the diagnostic process, offering specialized and accurate testing services that cater to a broad spectrum of patients.

The growth trends in this segment are propelled by technological advancements, increasing investment in healthcare facilities, and the rising prevalence of cancer. Hospitals are likely to maintain their dominance due to the high volume of patient interactions and treatment implementations. Meanwhile, diagnostic laboratories are benefitting from the move towards precision medicine and personalized treatment plans, positioning them as the fastest-growing segment in this landscape.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals are characterized by their extensive infrastructure, which allows for comprehensive patient care, assuming a dominant position in the liquid biopsy market. They leverage state-of-the-art technology, skilled personnel, and integrated services to provide timely diagnosis and treatment options. On the other hand, diagnostic laboratories are emerging as key players in this field, specializing in various testing methodologies, which enhance the accuracy and reliability of liquid biopsy results. Their adaptability to technological changes and focus on research and development foster innovative solutions, making them vital for the growing demand in personalized medicine. Together, these segments contribute significantly to the overall development and expansion of liquid biopsy capabilities.

## Competitive Benchmarking

The liquid biopsy market exhibits a dynamic competitive landscape, characterized by rapid advancements and a growing emphasis on precision medicine. Key growth drivers include the increasing prevalence of cancer, the demand for non-invasive diagnostic methods, and the integration of advanced technologies such as artificial intelligence (AI) in diagnostic processes. Major players such as Guardant Health (US), Roche (CH), and Thermo Fisher Scientific (US) are strategically positioned to leverage these trends. Guardant Health (US) focuses on innovation in genomic profiling, while Roche (CH) emphasizes its extensive portfolio in molecular diagnostics. Thermo Fisher Scientific (US) is enhancing its capabilities through strategic partnerships and technological advancements, collectively shaping a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the collective influence of key players is significant, as they drive technological advancements and set industry standards. This competitive structure fosters an environment where innovation is paramount, compelling companies to continuously evolve their offerings to meet the demands of healthcare providers and patients alike.

In October  Guardant Health (US) announced a collaboration with a leading Indian healthcare provider to expand its liquid biopsy services in the region. This strategic move is likely to enhance access to advanced genomic testing for cancer patients, thereby solidifying Guardant's presence in the Indian market. The partnership underscores the importance of local collaborations in driving market penetration and improving patient outcomes through tailored solutions.

In September  Roche (CH) launched a new liquid biopsy test aimed at early cancer detection, which is expected to significantly impact the diagnostic landscape. This innovation not only reinforces Roche's commitment to advancing precision medicine but also positions the company as a leader in the early detection segment. The introduction of such tests may lead to improved patient prognoses and a shift in treatment paradigms, highlighting the strategic importance of continuous innovation in this sector.

In August  Thermo Fisher Scientific (US) expanded its product portfolio by acquiring a small biotech firm specializing in liquid biopsy technologies. This acquisition is indicative of Thermo Fisher's strategy to enhance its technological capabilities and broaden its market reach. By integrating new technologies, the company aims to offer comprehensive solutions that cater to the evolving needs of healthcare professionals and patients, thereby strengthening its competitive position.

As of November  current trends in the liquid biopsy market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among key players are shaping the landscape, fostering innovation and enhancing service delivery. The competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, reliability in supply chains, and the ability to deliver innovative solutions. This shift suggests that companies that prioritize research and development, alongside strategic partnerships, will be better positioned to thrive in the future.

## Recent News & Developments

The India Liquid Biopsy Market has seen significant developments recently, with several companies actively trying to enhance their positions. In September 2023, Natera announced the expanding availability of its tests within the Indian healthcare system, aiming to improve the early detection of cancers. Concurrently, Roche Diagnostics is advancing its liquid biopsy technology for oncology applications, emphasizing the importance of non-invasive diagnostics. Illumina has also been focusing on partnerships with local laboratories to enhance genomic profiling capabilities.In terms of mergers and acquisitions, Cancer Genetics acquired Cernostics in August 2023, enabling a broader portfolio of liquid biopsy services in India.

This strategic acquisition is expected to strengthen Cancer Genetics' market presence in the rapidly growing oncology diagnostics sector. The market valuation for liquid biopsy companies in India is increasing significantly, driven by rising awareness, technological advancements, and a growing demand for early cancer detection methodologies. Additionally, in 2022, OncoStem Diagnostics received regulatory approval for its liquid biopsy test, providing another boost to its market position. Overall, the liquid biopsy market in India is poised for robust growth and is influenced by innovative technologies and strategic partnerships among key players.

## Report Scope

| MARKET SIZE 2024 | 363.96(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 402.25(USD Million) |
| MARKET SIZE 2035 | 1093.72(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.52% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Guardant Health (US), Exact Sciences (US), Freenome (US), GRAIL (US), Biocept (US), Foundation Medicine (US), Roche (CH), Thermo Fisher Scientific (US), Qiagen (DE) |
| Segments Covered | Application, Sample Type, Technology, End Use |
| Key Market Opportunities | Advancements in non-invasive cancer diagnostics drive growth in the liquid biopsy market. |
| Key Market Dynamics | Rising demand for non-invasive cancer diagnostics drives innovation and competition in the liquid biopsy market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What is the current valuation of the liquid biopsy market in India as of 2024?**
A: The liquid biopsy market in India was valued at $363.96 Million in 2024.

**Q: What is the projected market size for liquid biopsy in India by 2035?**
A: The market is projected to reach $1,093.72 Million by 2035.

**Q: What is the expected CAGR for the liquid biopsy market in India during the forecast period 2025 - 2035?**
A: The expected CAGR for the liquid biopsy market in India during 2025 - 2035 is 10.52%.

**Q: Which application segment holds the largest market share in the liquid biopsy market in India?**
A: The Cancer Diagnosis segment held a valuation of $145.58 Million in 2024 and is expected to grow significantly.

**Q: What are the key sample types used in the liquid biopsy market in India?**
A: The primary sample types include Blood, Urine, Saliva, Pleural Fluid, and Cerebrospinal Fluid, with Blood valued at $145.58 Million in 2024.

**Q: Which technology segment is anticipated to drive growth in the liquid biopsy market in India?**
A: Next Generation Sequencing, valued at $100.0 Million in 2024, is anticipated to drive growth in the technology segment.

**Q: What are the main end-use sectors for liquid biopsy in India?**
A: The main end-use sectors include Hospitals, Diagnostic Laboratories, Research Institutes, and Pharmaceutical Companies, with Diagnostic Laboratories valued at $120.0 Million in 2024.

**Q: Who are the key players in the liquid biopsy market in India?**
A: Key players include Guardant Health, Exact Sciences, Freenome, GRAIL, Biocept, Foundation Medicine, Roche, Thermo Fisher Scientific, and Qiagen.

**Q: How does the liquid biopsy market in India compare to other regions?**
A: While specific regional comparisons are not provided, the growth trajectory in India appears promising with a projected market size of $1,093.72 Million by 2035.

**Q: What factors are contributing to the growth of the liquid biopsy market in India?**
A: Factors contributing to growth include advancements in technology, increasing cancer prevalence, and rising demand for non-invasive diagnostic methods.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-liquid-biopsy-market-44663*